The Effects of Written Emotional Disclosure on Eating Disorder Pathology in a Clinical Eating Disordered Population

This study is not yet open for participant recruitment.

Verified by Penn State University, September 2008

Sponsored by:	Penn State University
Information provided by:	Penn State University
ClinicalTrials.gov Identifier:	NCT00766558

Purpose

A technique that has been found to be effective at relieving the physical and psychological symptoms associated with inhibiting emotions and emotional thoughts is written emotional disclosure. The goal of this study is to evaluate the effectiveness of written emotional disclosure on the remediation of eating disorder behaviour, cognitions, and management of emotions.

Condition
Anorexia Nervosa Bulimia Nervosa Eating Disorder

MedlinePlus related topics: Eating Disorders

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Study of the Efficacy of Written Emotional Disclosure on Eating Disorder Pathology

Further study details as provided by Penn State University:

Primary Outcome Measures:

Testing and behavioral changes [ Time Frame: 6-weeks ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	50
Study Start Date:	November 2008
Estimated Study Completion Date:	December 2010
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Groups/Cohorts
1
2
Written disclosure Participant is assigned a potential stress-producing topic for written disclosure.
Control group Participant assigned a non-stressful writing condition.

Eligibility

Ages Eligible for Study:	14 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients in the Penn State Hershey Adolescentand Adult Eating Disorders Partial Hospitalization Program

Criteria

Inclusion Criteria:

Willing to sign consent form

Exclusion Criteria:

Unwilling to sign consent form

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00766558

Contacts

Contact: Richard L Levine, MD	7175318006	rlevine@psu.edu
Contact: Martha P Levine, MD	7175317232	mlevine1@hmc.psu.edu

Locations

United States, Pennsylvania
Penn State College of Medicine
Hershey, Pennsylvania, United States, 17033

Sponsors and Collaborators

Penn State University

More Information

Responsible Party:	Kevin Gleeson, MD ( Penn State College of Medicine IRBs A, B, C and D )
Study ID Numbers:	28860
Study First Received:	October 3, 2008
Last Updated:	October 3, 2008
ClinicalTrials.gov Identifier:	NCT00766558
Health Authority:	United States: Institutional Review Board

Keywords provided by Penn State University:

anorexia
bulimia
eating disorder not otherwise specified

Study placed in the following topic categories:

Signs and Symptoms
Bulimia Nervosa
Signs and Symptoms, Digestive
Mental Disorders
Bulimia

Anorexia
Anorexia Nervosa
Eating Disorders
Hyperphagia

Additional relevant MeSH terms:

Pathologic Processes
Disease

ClinicalTrials.gov processed this record on January 16, 2009